NXTC vs. KZR, HOOK, PRTK, IMAB, TELO, RAPT, VERU, SYRS, SGMT, and CRVS
Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Kezar Life Sciences (KZR), Hookipa Pharma (HOOK), Paratek Pharmaceuticals (PRTK), I-Mab (IMAB), Telomir Pharmaceuticals (TELO), RAPT Therapeutics (RAPT), Veru (VERU), Syros Pharmaceuticals (SYRS), Sagimet Biosciences (SGMT), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "medical" sector.
Kezar Life Sciences (NASDAQ:KZR) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment.
NextCure has lower revenue, but higher earnings than Kezar Life Sciences. NextCure is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Kezar Life Sciences received 56 more outperform votes than NextCure when rated by MarketBeat users. However, 63.93% of users gave NextCure an outperform vote while only 58.01% of users gave Kezar Life Sciences an outperform vote.
NextCure's return on equity of -47.28% beat Kezar Life Sciences' return on equity.
In the previous week, Kezar Life Sciences had 1 more articles in the media than NextCure. MarketBeat recorded 1 mentions for Kezar Life Sciences and 0 mentions for NextCure. NextCure's average media sentiment score of 0.00 equaled Kezar Life Sciences'average media sentiment score.
Kezar Life Sciences presently has a consensus target price of $11.00, suggesting a potential upside of 1,466.95%. NextCure has a consensus target price of $6.00, suggesting a potential upside of 347.73%. Given NextCure's higher possible upside, analysts clearly believe Kezar Life Sciences is more favorable than NextCure.
Kezar Life Sciences has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 9.3% of Kezar Life Sciences shares are owned by company insiders. Comparatively, 13.3% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Kezar Life Sciences beats NextCure on 9 of the 15 factors compared between the two stocks.
Get NextCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NextCure Competitors List
Related Companies and Tools
